Pericardial effusion cytology: malignancy rates, patterns of metastasis, comparison with pericardial window, and genomic correlates
Journal of the American Society of Cytopathology · 2025
DOI: 10.1016/j.jasc.2024.12.005 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Society of Cytopathology, 2025. Verfasst von Vanda F Torous und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Pericardial Effusion, Pericardial Fluid, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Cytologic evaluation of pericardial fluid is essential for diagnosing malignant pericardial effusions secondary to metastatic disease and for guiding appropriate clinical management; however, large cohort and up-to-date studies on malignancy rates and distribution of primary tumor sites is lacking. MATERIALS AND METHODS: A retrospective analysis of pericardial fluid specimens from 2 large academic medical centers over a 10-year period was conducted. Clinical and specimen characteristics were correlated with cytologic diagnoses, and compared with surgical pathology pericardial specimens when available. In addition, genomic testing results were examined in a subset of malignant cases. RESULTS: A total of 1667 pericardial fluid specimens were evaluated, with 15.3% diagnosed as malignant. Lung cancer (50.6%) was by far the most common primary tumor causing malignant pericardial effusions, followed by breast (13.0%), hematolymphoid (12.6%), and gastrointestinal (6.1%) cancers. A subset of patients with paired cytology and surgical pathology pericardial specimens showed concordance in 84.2% of cases, with discordant cases more frequently presenting with a positive cytology but negative surgical pathology result. Genomic analysis of a subset of malignant pericardial effusions revealed the most frequently mutated genes to be TP53, KRAS, CDKN2A/B, and PIK3CA, with a larger proportion of high tumor mutational burden (≥10 muts/Mb) in pericardial fluid samples compared to primary or metastatic sites. CONCLUSIONS: While lung cancer is the most frequent cause of a cytology-confirmed malignant pericardial effusion, familiarity with relative frequencies of metastases from other sites can be particularly helpful, especially in the diagnostic work-up of an occult malignant pericardial effusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
- Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
- Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Electronic address: pvanderl@bidmc.harvard.edu.
Zitieren
APA
Torous, V. F., Pineda, C. M., Quintana, L. M., Chebib, I., & VanderLaan, P. A. (2025). Pericardial effusion cytology: malignancy rates, patterns of metastasis, comparison with pericardial window, and genomic correlates. Journal of the American Society of Cytopathology. https://doi.org/10.1016/j.jasc.2024.12.005
Vancouver
Torous VF, Pineda CM, Quintana LM, Chebib I, VanderLaan PA. Pericardial effusion cytology: malignancy rates, patterns of metastasis, comparison with pericardial window, and genomic correlates. Journal of the American Society of Cytopathology. 2025. doi:10.1016/j.jasc.2024.12.005
BibTeX
@article{Torous2025,
author = {Torous, Vanda F and Pineda, Cristiana M and Quintana, Liza M and Chebib, Ivan and VanderLaan, Paul A},
title = {Pericardial effusion cytology: malignancy rates, patterns of metastasis, comparison with pericardial window, and genomic correlates},
journal = {Journal of the American Society of Cytopathology},
year = {2025},
doi = {10.1016/j.jasc.2024.12.005}
}
EUVIMED